JP2023504196A - 胎盤由来の同種car-t細胞およびその使用 - Google Patents
胎盤由来の同種car-t細胞およびその使用 Download PDFInfo
- Publication number
- JP2023504196A JP2023504196A JP2022534239A JP2022534239A JP2023504196A JP 2023504196 A JP2023504196 A JP 2023504196A JP 2022534239 A JP2022534239 A JP 2022534239A JP 2022534239 A JP2022534239 A JP 2022534239A JP 2023504196 A JP2023504196 A JP 2023504196A
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- cells
- car
- cell
- peripheral blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002826 placenta Anatomy 0.000 title description 22
- 230000000735 allogeneic effect Effects 0.000 title description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 300
- 210000004027 cell Anatomy 0.000 claims abstract description 227
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 182
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 54
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 52
- 239000011886 peripheral blood Substances 0.000 claims abstract description 52
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 230000003169 placental effect Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 25
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 77
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 76
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 76
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 108091008874 T cell receptors Proteins 0.000 claims description 27
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 25
- 239000012636 effector Substances 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 20
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 20
- 208000024908 graft versus host disease Diseases 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 18
- 238000010361 transduction Methods 0.000 claims description 17
- 230000026683 transduction Effects 0.000 claims description 17
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 230000004083 survival effect Effects 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 12
- 238000012239 gene modification Methods 0.000 claims description 11
- 230000005017 genetic modification Effects 0.000 claims description 11
- 235000013617 genetically modified food Nutrition 0.000 claims description 11
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 108091033409 CRISPR Proteins 0.000 claims description 9
- 230000000770 proinflammatory effect Effects 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 8
- 238000010354 CRISPR gene editing Methods 0.000 claims description 8
- 102000001398 Granzyme Human genes 0.000 claims description 8
- 108060005986 Granzyme Proteins 0.000 claims description 8
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 238000003209 gene knockout Methods 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 7
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 7
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 7
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 7
- 229930192851 perforin Natural products 0.000 claims description 7
- 230000001177 retroviral effect Effects 0.000 claims description 7
- 238000001890 transfection Methods 0.000 claims description 7
- 230000003827 upregulation Effects 0.000 claims description 7
- 230000004580 weight loss Effects 0.000 claims description 7
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims description 4
- 102000004503 Perforin Human genes 0.000 claims description 4
- 108010056995 Perforin Proteins 0.000 claims description 4
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 3
- 102100033467 L-selectin Human genes 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 claims description 3
- 230000005880 cancer cell killing Effects 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 23
- 241000713666 Lentivirus Species 0.000 description 22
- 241001430294 unidentified retrovirus Species 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 18
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 18
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 18
- 230000004068 intracellular signaling Effects 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000003501 co-culture Methods 0.000 description 11
- 239000012642 immune effector Substances 0.000 description 11
- 229940121354 immunomodulator Drugs 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 210000003071 memory t lymphocyte Anatomy 0.000 description 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 102100024263 CD160 antigen Human genes 0.000 description 3
- -1 CDl la Proteins 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005206 flow analysis Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100039904 Integrin alpha-D Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000027581 NK cell receptors Human genes 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000011129 allogeneic cell therapy Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 108010083224 human transframe polypeptide Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
出発物質の胎盤血(ヒト臍帯血(UCB)および/またはヒト胎盤灌流液(HPP)の両方を含む)は、LifebankUSAを通してインフォームドコンセントによって採取される。採取後、HetastarchによるRBC沈降またはFicoll-Paqueによる密度勾配細胞分離を用いて、出発物質を単核細胞(MNC)について濃縮する。次いで、CD25+T調節T細胞(Treg)を枯渇させるためにMNCの陽性選択プロセスを行った後、Militenyiビーズ細胞分離キットを使用してCD4+およびCD8+T細胞を陽性選択する。細胞を凍結する前に、血清学的および無菌検査、ならびに表現型分析のために、単離されたT細胞のアリコートを採取する。
非修飾P-T細胞:
単離されたP-T細胞を解凍し、CD4+CD25+CD127-Tregの除去(T細胞単離ステップの前に含めることができる)のためにMiltenyi抗CD25ビーズを使用してCD25枯渇を行い、Invitrogenの抗CD3/抗CD28Dynabeads(1:1ビーズ:細胞比)を使用して、またはMiltenyiの抗CD3/抗CD28ナノ粒子Transact(1:100体積希釈)を使用して活性化する。次いで、細胞を、100IU/mLのIL-2、10ng/mLのIL-7+10ng/mLのIL-15、または100IU/mLのIL-2+10ng/mLのIL-7を用いて増殖する。追加の再刺激を12~14日目に完了し、倍数増殖を最大化するために、Grex容器内で21日目まで細胞を増殖させる。
単離されたT細胞(凍結前にCD25枯渇を受けた)を解凍し、Miltenyiの抗CD3/抗CD28ナノ粒子Transact(1:100体積希釈)を使用して活性化した。次いで、100IU/mLのIL-2を用いて、Grex容器内で細胞を増殖させた。3日目に、ウイルスのプレスピン法を用いて、レトロネクチンでコーティングされたプレート上で、CD19 CARレンチウイルス(LV)またはレトロウイルス(RV)のいずれかで細胞を形質導入した。次いで、2~3日毎に培地供給を行いながら、15日目まで細胞を培養した。
-マウス(Ms)scFv CD19 CARレンチウイルス(LV)
-JL4.19(EF1a-CD8-scFv-CD8-HTM-BBz)(SBIベクター、UPENN CAR19)
-Vector Builder(VB)およびSignaGenによって生成された研究グレードのウイルス
-ヒト(Hu)scFv CD19 CARレンチウイルス(LV)
-JL huCAR19(CD8-signal-VL-linker-VH-CD8HTM-BBz)(Hu scFvを除いてUPENN CARと同一)
-JK1 huCAR19(CD8-signal-VL-linker-VH-CD8HTM-28z)(「NCI CAR」、JLよりも4aa長いCD8ヒンジおよび膜貫通ドメイン、CD28共刺激ドメイン、Hu scFv)
-JK2 huCAR19(CD8-シグナル-VL-リンカー-VH-CD8HTM-BBz)(NCI CARと同じであるが、41BB共刺激ドメインを有する、Hu scFv)
-3つのヒト配列はすべて研究グレードであり、SignaGenによって生成される
-マウス(Ms)scFv CD19 CARレトロウイルス(RV)
-Sorrento Therapeuticsによって生成および提供される
がん細胞株に対する15日目のP-CD19 CAR-T細胞の細胞溶解活性
P-CD19 CAR T細胞のインビトロでの機能活性を、Kinetic ACEA細胞毒性アッセイにおいて、CD19+バーキットリンパ腫(Daudi)およびCD19+急性リンパ芽球性白血病(Nalm6)細胞株と比較して評価し、P-T細胞の活性を、PBMCのMs CD19 CAR RVと比較した(n=6)。CD19-K562細胞を、非特異的な死滅を評価するための陰性対照として含めた。
さらに、P-CD19 CAR T細胞のインビトロ機能活性を、サイトカイン放出アッセイにおいて、CD19+バーキットリンパ腫(Daudi)およびCD19+急性リンパ芽球性白血病(Nalm6)細胞株と比較して評価した。CD19-K562細胞を、P-CD19 CAR T細胞の非特異的な死滅を評価するための標的として含めた。P-CD19 CAR-T細胞を、1:1のE:T比で24時間、CD19+/-標的と共培養し、細胞培養上清を回収し、様々なサイトカインおよびエフェクタータンパク質の分泌について分析した。
P-CD19 CAR T細胞のインビボでの抗腫瘍活性を、NSGマウスにおける播種性リンパ腫異種移植片モデルを使用して評価した。Daudi細胞(3×106)を発現するルシフェラーゼを0日目に静脈内(IV)注射し、続いてP-CD19 CAR T細胞をIV注射した。P-T細胞を、表1に概説したCD8+CD19 CAR+の頻度に従って投与した(P-T:RV:7日目に1用量の14×106、LV:7日目に1用量の20×106、または7日目、10日目および14日目に3用量の20×106)。生物発光イメージング(BLI)および生存率を、主要研究エンドポイントとして用いた。
TRAC遺伝子座の第1のエクソンに対するガイドRNA(gRNA)を用いてTRACを標的化した。P-T培養の6~8日目に、Cas9およびgRNAの化学修飾したRNA形態を、Nucleofection(Lonza)によりP-T細胞にトランスフェクトした。TCRα/βまたはCD3に対する抗体を用いたフローサイトメトリーによって、遺伝子組換え効率をモニタリングした。
TRACノックアウトによる機能喪失の検証は、P-T CD19 CAR-NT(非トランスフェクト)およびP-T CD19 CAR-TRAC KO細胞を抗CD3/CD28ナノ粒子で再刺激し、細胞を4日間培養することによって完了した。
2つの独立したアッセイを使用して、P-T細胞に対するPMBCの、またはPBMCに対するP-T細胞の同種反応性を測定した。最初のアッセイでは、4時間の共培養において、一方のドナーから別のドナーへの細胞の死滅活性として同種反応性が測定された。標的細胞をPKH26で標識し、細胞毒性を全標的細胞に対する死滅した標的細胞の割合として表した。
P-T細胞の同種反応性をさらに評価するために、HLAミスマッチのPKH26標識P-Tを、一方向混合リンパ球反応(MLR)において、CFSEおよびマイトマイシン-C(MMC)で処置したPBMCと1:1の比で4日間共培養して、P-T細胞対PBMCの任意の同種反応性(GvHDの可能性)を評価した。アッセイ読み出しには、P-T細胞の倍数増殖、P-T細胞上のT細胞活性化マーカーCD25の上方制御、ならびにHLAミスマッチPBMCに応答したP-T細胞による炎症促進性サイトカインおよびエフェクタータンパク質の分泌が含まれた。
同様に、HLAミスマッチP-T CD19 CAR T細胞に対するPBMCの同種反応性も評価した。この設定では、一方向MLRにおいて、PBMCをPKH26で標識し、CFSEおよびマイトマイシン-C(MMC)で処置したP-CD19 CAR T細胞と1:1の比で4日間共培養して、PBMC細胞対P-Tの同種反応性(宿主対移植片)を評価した。アッセイ読み出しには、PBMCの倍数増殖、PBMC細胞上のT細胞活性化マーカーCD25の上方制御、ならびにHLAミスマッチP-CD19 CAR T細胞に応答したPBMC細胞による炎症促進性サイトカインおよびエフェクタータンパク質の分泌が含まれた。
GvHDのNCGマウスモデルにおいて、非修飾の21日間増殖させたP-T細胞の同種反応性(異種-同種反応性)を試験した。このモデルでは、PBMCは、体重減少として測定され得るGvHDを引き起こす。3つのドナーからのCD25枯渇P-T細胞3000万個および対照PMBCを、IV経路を介してNCGマウスに注射した。動物の体重を経時的にモニタリングした。
この試験の目的は、ヒト臍帯血CD34+細胞(Hu-CD34 NSG)を生着した非肥満糖尿病(NOD)スキッドIL2Rgammanull(NSG)マウスにおける同種GvHD、神経毒性およびサイトカイン放出症候群を含む、CyCART-19またはCyCART-19 TRAC KOに関連する潜在的な毒性を評価することであった。
Claims (50)
- キメラ抗原受容体(CAR)を発現するT細胞集団であって、前記T細胞が、胎盤T細胞であり、前記CARが、レトロウイルスベクターを用いたウイルス形質導入によって前記細胞に導入されている、T細胞集団。
- 前記胎盤T細胞が、臍帯血T細胞、胎盤灌流液T細胞、またはそれらの混合物である、請求項1に記載のT細胞集団。
- 前記胎盤T細胞が、臍帯血T細胞である、請求項1に記載のT細胞集団。
- 前記胎盤T細胞が、臍帯血T細胞と胎盤灌流液T細胞との混合物である、請求項1に記載のT細胞集団。
- CAR+T細胞の優勢な亜集団が、T scm/ナイーブ表現型を有する、請求項1~4のいずれか一項に記載のT細胞集団。
- 前記CAR+T scm/ナイーブ細胞の亜集団が、前記CAR+T細胞集団の約30%超、前記CAR+T細胞集団の約40%超、前記CAR+T細胞集団の約45%超、または前記CAR+T細胞集団の約50%超を占める、請求項5に記載のT細胞集団。
- エフェクターメモリー表現型(T eff)を有する前記CAR+T細胞の亜集団が、前記CAR+T細胞集団の約75%未満、前記CAR+T細胞集団の約70%未満、前記CAR+T細胞集団の約60%未満、前記CAR+T細胞集団の約50%未満、前記CAR+T細胞集団の約40%未満、前記CAR+T細胞集団の約35%未満、または前記CAR+T細胞集団の約30%未満を占める、請求項1~6のいずれか一項に記載のT細胞集団。
- セントラルメモリー表現型(Tcm)を有する前記CAR+T細胞の亜集団が、前記CAR+T細胞集団の約10%未満、前記CAR+T細胞集団の約8%未満、前記CAR+T細胞集団の約6%未満、前記CAR+T細胞集団の約5%未満、前記CAR+T細胞集団の約4%未満、または前記CAR+T細胞集団の約3%未満を占める、請求項1~7のいずれか一項に記載のT細胞集団。s
- CD8+である前記CAR+T細胞の亜集団の相対存在量が、CD4+であるCAR+T細胞の亜集団の相対存在量の50%超であり、前記CD4+であるCAR+T細胞の亜集団の前記相対存在量の60%超であり、前記CD4+であるCAR+T細胞の亜集団の前記相対存在量の70%超であり、前記CD4+であるCAR+T細胞の前記相対存在量の80%超であり、前記CD4+であるCAR+T細胞の亜集団の前記相対存在量の90%超であり、前記CD4+であるCAR+T細胞の亜集団の前記相対存在量の100%超である、請求項1~8のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりも増加した抗腫瘍活性を有する、請求項1~9のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、宿主に対する免疫原性を低下させるための遺伝子改変を含む、請求項1~10のいずれか一項に記載のT細胞集団。
- 前記遺伝子改変が、遺伝子ノックアウトである、請求項11に記載のT細胞集団。
- 前記遺伝子ノックアウトが、T細胞受容体(TCR)ノックアウトである、請求項12に記載のT細胞集団。
- 前記遺伝子ノックアウトが、T細胞受容体α定常領域(TRAC)ノックアウトである、請求項13に記載のT細胞集団。
- 前記遺伝子改変が、トランスフェクション、レトロウイルス形質導入、またはレンチウイルス形質導入によってもたらされる、請求項12~14のいずれか一項に記載のT細胞集団。
- さらなる遺伝子改変が、CRISPR技術の使用によってもたらされる、請求項12~15のいずれか一項に記載のT細胞集団。
- 前記TRACノックアウトが、混合リンパ球反応(MLR)アッセイにおいて、前記TRACノックアウトなしのT細胞集団と比較して末梢血単核球に対する同種反応性が低下している、請求項1~16のいずれか一項に記載のT細胞集団。
- 前記同種反応性の低下が、前記T細胞集団上のCD25の発現の低下または上方制御の低下を含む、請求項16に記載のT細胞集団。
- 前記同種反応性の低下が、炎症促進性またはエフェクタータンパク質の発現の低下または上方制御の低下を含む、請求項16に記載のT細胞集団。
- 前記炎症促進性またはエフェクタータンパク質が、IFN-g、TNF-α、パーフォリン、グランザイムB、およびこれらの組み合わせからなる群から選択される、請求項19に記載のT細胞集団。
- 前記同種反応性の低下が、前記末梢血単核球の増殖(proliferation)/増殖(expansion)の低下を含む、請求項16に記載のT細胞集団。
- 前記TRACノックアウトが、インビボGVHDモデルにおいて同種反応性を欠いているか、またはそれが低下している、請求項1~21のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCD45RAを発現する細胞の割合が高い、請求項1~22のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCD27を発現する細胞の割合が高い、請求項1~23のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCCR7を発現する細胞の割合が高い、請求項1~24のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCD127を発現する細胞の割合が高い、請求項1~25のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCD57を発現する細胞の割合が低い、請求項1~26のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCD62Lを発現する細胞の割合が高い、請求項1~27のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもCD25を発現する細胞の割合が低い、請求項1~28のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもLag-3+を発現する細胞の割合が高い、請求項1~29のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりもTim-3を発現する細胞の割合が低い、請求項1~30のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、末梢血単核球T細胞集団よりも多いがん細胞株のインビトロでの死滅を示す、請求項1~31のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビトロチャレンジで、がん細胞株に対して末梢血単核球T細胞集団よりも多くの量のパーフォリンを発現する、請求項1~32のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビトロチャレンジで、がん細胞株に対して末梢血単核球T細胞集団よりも多くの量のGM-CSFを発現する、請求項1~33のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビトロチャレンジで、がん細胞株に対して末梢血単核球T細胞集団よりも多くの量のTNF-αを発現する、請求項1~34のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビトロチャレンジで、がん細胞株に対して末梢血単核球T細胞集団よりも多くの量のIL-2を発現する、請求項1~35のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビトロチャレンジで、がん細胞株に対して末梢血単核球T細胞集団よりも多くの量のグランザイムBを発現する、請求項1~36のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビボがんモデルにおいて、末梢血単核球T細胞集団よりも高い生存率をもたらす、請求項1~37のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビボがんモデルにおいて、末梢血単核球T細胞集団よりも少ない体重減少をもたらす、請求項1~38のいずれか一項に記載のT細胞集団。
- 前記T細胞集団が、インビボがんモデルにおいて、末梢血単核球T細胞集団よりも少ない移植片対宿主病(GvHD)をもたらす、請求項1~39のいずれか一項に記載のT細胞集団。
- 前記末梢血単核球T細胞集団が、前記CARも発現する、請求項23~40のいずれか一項に記載のT細胞集団。
- 前記CARが、トランスフェクションによって前記末梢血単核球T細胞集団に導入されている、請求項41に記載のT細胞集団。
- 前記CARが、ウイルス形質導入によって前記末梢血単核球T細胞集団に導入されている、請求項41に記載のT細胞集団。
- 前記CARが、レトロウイルスベクターを用いたウイルス形質導入によって前記末梢血単核球T細胞集団に導入されている、請求項43に記載のT細胞集団。
- 前記CARが、レンチウイルスベクターを用いたウイルス形質導入によって前記末梢血単核球T細胞集団に導入されている、請求項43に記載のT細胞集団。
- がんまたはその症状の治療を必要とする患者においてがんまたはその症状を治療する方法であって、前記患者の前記がんまたはその症状を緩和するのに有効な量の請求項1~38のいずれか一項に記載のT細胞集団を前記患者に投与するステップを含む、方法。
- 前記がんが、血液がんである、請求項46に記載の方法。
- 前記血液がんが、B細胞がんである、請求項47に記載の方法。
- 前記がんが、CD19+がんである、請求項46~48のいずれか一項に記載の方法。
- 前記T細胞集団が、前記患者と同種である、請求項46~49のいずれか一項に記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943760P | 2019-12-04 | 2019-12-04 | |
US62/943,760 | 2019-12-04 | ||
US201962944349P | 2019-12-05 | 2019-12-05 | |
US62/944,349 | 2019-12-05 | ||
US202063035432P | 2020-06-05 | 2020-06-05 | |
US63/035,432 | 2020-06-05 | ||
PCT/US2020/063473 WO2021113759A1 (en) | 2019-12-04 | 2020-12-04 | Placenta-derived allogeneic car-t cells and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023504196A true JP2023504196A (ja) | 2023-02-01 |
JPWO2021113759A5 JPWO2021113759A5 (ja) | 2024-04-09 |
Family
ID=74068688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022534239A Pending JP2023504196A (ja) | 2019-12-04 | 2020-12-04 | 胎盤由来の同種car-t細胞およびその使用 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4069258A1 (ja) |
JP (1) | JP2023504196A (ja) |
KR (1) | KR20220110199A (ja) |
CN (1) | CN115397442A (ja) |
AU (1) | AU2020397953A1 (ja) |
BR (1) | BR112022010887A2 (ja) |
CA (1) | CA3161789A1 (ja) |
IL (1) | IL293462A (ja) |
MX (1) | MX2022006704A (ja) |
WO (1) | WO2021113759A1 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0985039T3 (da) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Kunstige antistof-polypeptider |
US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
AU2015360845B2 (en) * | 2014-12-12 | 2020-11-26 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
IL303247A (en) * | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
US11896614B2 (en) * | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3559214A1 (en) * | 2016-12-21 | 2019-10-30 | UCL Business PLC | Therapeutic cells |
BR112021010132A2 (pt) * | 2018-11-30 | 2021-08-24 | Celularity Inc. | Células car-t alogênicas derivadas da placenta e usos da mesmas |
-
2020
- 2020-12-04 BR BR112022010887A patent/BR112022010887A2/pt not_active Application Discontinuation
- 2020-12-04 KR KR1020227018403A patent/KR20220110199A/ko active Search and Examination
- 2020-12-04 CN CN202080084124.6A patent/CN115397442A/zh active Pending
- 2020-12-04 IL IL293462A patent/IL293462A/en unknown
- 2020-12-04 JP JP2022534239A patent/JP2023504196A/ja active Pending
- 2020-12-04 EP EP20829756.4A patent/EP4069258A1/en active Pending
- 2020-12-04 WO PCT/US2020/063473 patent/WO2021113759A1/en unknown
- 2020-12-04 CA CA3161789A patent/CA3161789A1/en active Pending
- 2020-12-04 AU AU2020397953A patent/AU2020397953A1/en active Pending
- 2020-12-04 MX MX2022006704A patent/MX2022006704A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220110199A (ko) | 2022-08-05 |
CN115397442A (zh) | 2022-11-25 |
CA3161789A1 (en) | 2021-06-10 |
IL293462A (en) | 2022-07-01 |
BR112022010887A2 (pt) | 2022-08-23 |
EP4069258A1 (en) | 2022-10-12 |
WO2021113759A1 (en) | 2021-06-10 |
MX2022006704A (es) | 2022-11-09 |
AU2020397953A8 (en) | 2022-05-26 |
AU2020397953A1 (en) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6879910B2 (ja) | Cart細胞における遺伝子発現の改変およびその使用 | |
RU2751362C2 (ru) | Способы получения экспрессирующих химерный антигенный рецептор клеток | |
EP3166968B1 (en) | Compositions and methods of chimeric autoantibody receptor t cells | |
JP2023029373A (ja) | キメラ抗体受容体(CARs)の組成物およびその使用方法 | |
US20220025001A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
KR20200069358A (ko) | 키메라 항원 수용체 발현 세포의 제조 방법 | |
JP2021534802A (ja) | 複数のhla−gアイソフォームに対するキメラ抗原レセプター | |
JP2020537537A (ja) | 抗hla−a2抗体及びその使用方法 | |
KR20180050413A (ko) | Hiv 감염을 치료하기 위해 t 세포를 리디렉션시키는 방법 | |
US20220064255A1 (en) | Anti-tcr antibody molecules and uses thereof | |
EP4058483A1 (en) | Anti-tcr antibody molecules and uses thereof | |
US20220118014A1 (en) | Placenta-derived allogeneic car-t cells and uses thereof | |
JP2024532851A (ja) | B細胞受容体に特異的なキメラ抗原受容体のための組成物および方法 | |
EP4218777A2 (en) | Methods and compositions for cells expressing a chimeric intracellular signaling molecule | |
JP2023504196A (ja) | 胎盤由来の同種car-t細胞およびその使用 | |
WO2023225634A2 (en) | Methods for the enhancement of therapeutic effect of car-t cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230711 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240326 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240326 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240903 |